Durability of first line antiretroviral therapy: Reasons and predictive factors for modifications in a Swaziland Cohort

Journal of Antivirals and Antiretrovirals

Volumn 4, Issue 1, 2012, Pages 014-020

  Takuva, Simbarashe ^a,b,e   Louwagie, Goedele ^a   Zuma, Khangelani ^b,c   Okello, Velephi ^d  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b Mbabane Government Hospital Antiretroviral Therapy Unit   (Swaziland)

^c HUMAN SCIENCES RESEARCH COUNCIL   (South Africa)

^d Government of the Kingdom of Eswatini   (Swaziland)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antiretroviral drug modifications; First line ART; Regimen durability; Swaziland

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GYNECOMASTIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAIL COLOR DEFECT; OUTPATIENT; PERIPHERAL NEUROPATHY; RASH; RISK FACTOR; SWAZILAND; VOMITING;

EID: 84857604296     PISSN: None     EISSN: 19485964     Source Type: Journal    
DOI: 10.4172/jaa.1000040     Document Type: Article

References (26)

1. Swaziland Demographic Health Survey Report 2008 (2008) Ministry of Health and Social Welfare/Measure DHS Project.
2. Antiretroviral therapy for HIV infection in adults and adolescents (2006) Recommendations for a public health approach. World Health Organization.
3. Ministry of Health and Social Welfare, Swaziland (2006) National Guidelines for Antiretroviral Treatment and Post-exposure Prophylaxis for Adults and Adolescents.
4. Van Roon EN, Verzijl JM, Juttmann JR, Juttmann JR, Lenderink AW, et al. (1999) Incidence of discontinuation of highly active antiretroviral therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 20: 290-294.
5. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, et al. (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358: 1322-1327.
6. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeters or less. N Engl J Med 337: 725-733.
7. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, et al. (2000) Insights into the reasons for discontinuation of the first highly active antiretroviral (HAART) regimen in a cohort aof antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 14: 499-507.
8. Kirstein LM, Greenblatt RM, Anastos K, Levine A, French AL, et al. (2002) Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 29: 495-503.
9. Boulle A, Orrel C, Kaplan R, van Cutsem G, McNally M, et al. (2007) Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 12: 753-760.
10. Australian HIV Observational Database (2002) Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 3: 28-36.
11. Deeks SG, Smith M, Holodniy M, Kahn JO (1997) HIV-1 protease inhibitors. A review for clinicians. JAMA 277: 145-153.
12. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents (2009) World Health Organization.
13. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, et al. (2003) Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr 54: 63-70.
14. Kirk O, Gerstoft J, Pedersen C, Nielsen H, Obel N, et al. (2001) Low body weight and type of protease inhibitor predict discontinuation and treatment limiting adverse drug reactions among HIV infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. HIV Med 2: 43-51.
15. Ssali F, Stöhr W, Munderi P, Reid A, Walker AS, et al. (2006) Prevalence, Incidence, predictors and timing of severe anaemia following initiation of zidovudine containing regimens in adults with HIV infection within the DART Trial. Antivir Ther 11: 741-749.
16. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887-895.
17. Centers for Disease control and prevention (2001) Serious adverse events attributed to nevirapine regimens for post exposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWRMorb Mortal Wkly Rep 49: 1153-1156.
18. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM (2002) Incidence and risk factors for severe hepatotoxicity associated with antiretroviral therapy. J Infect Dis 186: 23-31.
19. Youle M, Sawyer W (1998) For the HIV Health Economics Collaboration. Reasons for discontinuation of antiretroviral treatment: A clinical survey. AIDS 12: 186.
20. Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, et al. (2002) Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort. AIDS 16: 737-745.
21. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, et al. (2007) Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 8: 679-688.
22. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296.
23. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
24. Messou E, Anglaret X, Duvignac J, Konan-N'dri E, Komena E, et al. (2010) Antiretroviral treatment changes in adults from Cote d'Ivoire: the roles of tuberculosis and pregnancy. AIDS 24: 93-99.
25. Hänsel A, Bucher HC, Nüesch R, Battegay M (2001) Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitornaïve HIV-infected patients. J Acquir Immune Defic Syndr 26: 191-193.
26. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, et al. (2001) Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 15: 185-194.